

Causal Evaluation of Laboratory Markers in Type 2 Diabetes on Cancer and Vascular Diseases Using Various Mendelian Randomization Tools

1 Heejin Jin^{1,2}, Sanghun Lee^{3*}, Sungho Won^{1,4,5*}

2 ¹Department of Public Health Sciences, Seoul National University, Seoul, Republic of Korea

3 ²Medical Research Collaborating Center, Department of Biostatistics, Seoul National University
4 Boramae Hospital, Seoul, Republic of Korea

5 ³Department of Medical Consilience, Graduate School, Dankook University, Yongin-si, Republic of
6 Korea

7 ⁴Institute of Health and Environment, Seoul National University, Seoul, South Korea

8 ⁵RexSoft Corp, Seoul, South Korea

9 * **Correspondence:**

10 Sungho Won, won1@snu.ac.kr

11 Sanghun Lee, sanghunlee73@gmail.com

12 **Keywords: Mendelian randomization, instrumental variables analysis, causal relationship, risk**
13 **factor, fasting glucose, 2-h postload glucose, glycated hemoglobin A1c**

14 Abstract

15 Multiple studies have demonstrated the effects of type 2 diabetes (T2D) on various human diseases;
16 however, most of these were observational epidemiological studies that suffered from many potential
17 biases including reported confounding and reverse causations. In this article, we investigated whether
18 cancer and vascular disease can be affected by T2D-related traits, including fasting plasma glucose
19 (FPG), 2-h postprandial plasma glucose (2h-PG), and glycated hemoglobin A1c (HbA1c) levels, by
20 using Mendelian randomization (MR). The summary statistics for FPG, 2h-PG, and HbA1c were
21 obtained through meta-analyses of large-scale genome-wide association studies that included data
22 from 133,010 non-diabetic individuals from collaborating Meta-Analysis of Glucose and Insulin
23 related traits Consortium studies. Thereafter, based on the statistical assumptions for MR analyses,
24 the most reliable approaches including inverse-variance-weighted (IVW), MR-Egger, MR-Egger
25 with a simulation extrapolation (SIMEX), weighted median and MR-Pleiotropy RESidual Sum and
26 Outlier (MR-PRESSO) methods were applied to identify traits affected by FPG, 2h-PG, and HbA1c.
27 We found that coronary artery disease is affected by FPG, as per the IVW [log odds ratio (logOR):
28 0.21; $P=0.012$], MR-Egger (SIMEX) (logOR: 0.22; $P=0.014$), MR-PRESSO (logOR: 0.18;
29 $P=0.045$), and weighted median (logOR: 0.29; $P<0.001$) methods, but not as per the MR-Egger
30 (logOR: 0.13; $P=0.426$) approach. Furthermore, low-density lipoprotein cholesterol levels are
31 affected by HbA1c, as per the IVW (beta (B): 0.23; $P=0.015$), MR-Egger (B: 0.45; $P=0.046$), MR-
32 Egger (SIMEX) (B: 0.27; $P=0.007$), MR-PRESSO (B: 0.14; $P=0.010$), and the weighted median (B:
33 0.15; $P=0.012$) methods. Further studies of the associated biological mechanisms are required to
34 validate and understand the disease-specific differences identified in the TD2-related causal effects of
35 each trait.

36

37 1 Introduction

38 Type 2 diabetes (T2D) is characterized by high blood sugar, insulin resistance, and a relative lack of
39 insulin and represents a common metabolic disorder worldwide. In its early stage, T2D is easy to
40 ignore due to the lack of symptoms; however, chronic or poorly controlled T2D leads to eventually
41 disabling or life-threatening complications. Numerous epidemiological studies have consistently
42 demonstrated increased risks of cancer, vascular disease, nerve damage, and poor health-related
43 outcomes in T2D patients (De Vegt et al., 1999;Laakso, 1999;Tsilidis et al., 2015), resulting in a
44 shorter life expectancy (Collaboration, 2011). The main T2D-related complications reported in large-
45 scale epidemiological studies tend to be malignant solid tumors (Johnson et al., 2012) and
46 cardiovascular disease, including ischemic heart disease and stroke (Nesto, 2001;Bax et al.,
47 2007;Gleissner et al., 2007;Young et al., 2009). However, the causal relationship between T2D and
48 diverse health-related outcomes needs to be investigated and compared.

49 Fasting plasma glucose (FPG) levels ≥ 126 mg/dL or post-challenge 2-h plasma glucose (2h-PG)
50 levels ≥ 200 mg/dL in a 75-g 2-h oral glucose tolerance test (2h-OGTT) have been used as diagnostic
51 criteria for T2D. Additionally, hemoglobin A1c (HbA1c) levels $\geq 6.5\%$ were added to these
52 diagnostic criteria in 2010 (Gavin III et al., 1997;Association, 2010). The three tests (FPG, 2h-PG,
53 and HbA1c) are dependent on blood glucose metabolism status. Specifically, FPG assesses the state
54 of stable sugar levels in the body following a temporary increase in externally administered sugar.
55 The 2h-OGTT indicates how efficiently insulin is processed during metabolism in response to
56 increased externally administered glucose. HbA1c reflects the average blood sugar level until
57 immediately before the test and not at the time of sample collection, because hemoglobin increases
58 with time and according to glucose concentration (Nathan et al., 2007;Nathan et al., 2008).
59 Therefore, it is necessary to investigate the causal effects of these three T2D-related traits in the
60 blood and how they differ in subsequent pathological disorders.

61 To efficiently identify causal associations between T2D-related traits and various phenotypes without
62 potential biases or confounding and/or reverse causations, Mendelian randomization (MR) can be
63 used to assess how genetic variants act as instruments for instrumental variable (IV) analysis aimed
64 at estimating the causal effect of one trait on another. Using genetic variants as instruments, which
65 are not associated with conventional confounders of observational studies, allows the MR approach
66 to be considered analogous to randomized controlled trials (Burgess and Thompson, 2015). MR
67 analysis requires three assumptions: 1) IVs are strongly associated with intermediate exposure, 2) IVs
68 are independent of confounders, and 3) IVs affect outcomes only through the exposure path. If these
69 assumptions hold, an inverse-variance-weighted (IVW) method provides the most efficient and
70 unbiased estimates of causal effects (Burgess et al., 2020). Various MR methods have been proposed
71 for providing a more robust approach under weaker assumptions (Burgess et al., 2013;Bowden et al.,
72 2015;Bowden et al., 2016a;Bowden et al., 2016b;Verbanck et al., 2018).

73 The aim of this study was to assess the causal effect of T2D-related traits (FPG, 2h-PG, and HbA1c)
74 on cancers and vascular diseases via MR analysis using several methods, including those measuring
75 sensitivity in the MR-Base platform database (Hemani et al., 2016).

76 2 Materials and Methods

77 2.1 Exposure datasets

78 The exposure traits of interest were FPG, 2h-PG, and HbA1c. The summary statistics for T2D-related
79 traits were obtained through large-scale genome-wide association study (GWAS) meta-analyses of

80 133,010 non-diabetic individuals from collaborating studies within the Meta-Analysis of Glucose and
81 Insulin related traits Consortium (MAGIC) (Scott et al., 2012). In most of these studies, participants
82 were of European ancestry and adults. A total of ~2.5 million genome-wide directly genotyped or
83 imputed autosomal single-nucleotide polymorphisms (SNPs) were reported, including 36, 9, and 11
84 SNPs with genome-wide significant ($P < 5 \times 10^{-8}$) associations with FPG, 2h-PG, and HbA1c,
85 explaining 4.8%, 1.7%, and 2.4% of the variance in the trait, respectively. Among these, SNPs were
86 selected as IV candidates not in linkage disequilibrium (LD; $r^2 < 0.001$) or within 10,000 kb of an
87 established signal. To specify final IV sets, available genetic instruments for assessing outcome traits
88 of interest were explored via the MR-Base platform database (<https://www.mrbase.org/>) or through
89 the R package ‘TwoSampleMR’ (<https://rdrr.io/github/MRCIEU/TwoSampleMR/>). To reflect the
90 same reference strand between exposure and outcome, alleles and effects were harmonized using
91 effect/non-effect alleles and minor allele frequency for palindromic SNPs.

92 2.2 Outcome datasets

93 Human phenotypes were divided into two categories of diseases or traits known to be related to T2D.
94 The first category was cancer at major sites: breast, gall bladder, lung [adenocarcinoma and
95 squamous cell (SC) carcinoma], ovarian, pancreatic, and thyroid (differentiated types). The second
96 category was vascular disease: coronary kidney disease (CKD), coronary artery disease (CAD),
97 stroke, cardio-embolic stroke, small-vessel stroke, and high-density lipoprotein (HDL)/low-density
98 lipoprotein (LDL) cholesterol levels. We obtained summary SNP-outcome associations with a total
99 of 14 human health phenotypes through the MR-BASE platform. Additionally, information regarding
100 each outcome trait of interest was extracted (e.g., author/study/consortium name, number of cases
101 and controls, publication year, PubMed ID, study population, unit, etc.) and listed in Table 1.

102 2.3 MR assumptions

103 The assumptions of MR studies can be represented using causal directed acyclic graphs (DAG)
104 (Figure 1). In a DAG, the genetic variant G_j ($j=1, 2, \dots, J$) and the exposure, X , are denoted as γ_j , and
105 the association between the genetic variant, G_j , and the outcome, Y , is denoted as α_j . Associations
106 between a confounding factor (U) and G_j , X , and Y are denoted as ψ_j , K_x , and K_y , respectively. In a
107 two-sample MR setting, we refer to $\hat{\gamma}_j$ as an estimate from the j^{th} SNP-exposure association (with
108 variance $\sigma_{X_j}^2$) from sample 1 and $\hat{\alpha}_j$ as an estimate from the j^{th} SNP-outcome association (with
109 variance $\sigma_{Y_j}^2$) from sample 2.

$$110 \text{ Sample 1: } \hat{\gamma}_j = \gamma_j + k_x \varphi_j + \epsilon_{X_j}, \text{ var}(\epsilon_{X_j}) = \sigma_{X_j}^2$$

$$111 \text{ Sample 2: } \hat{\alpha}_j = \alpha_j + k_y \varphi_j + \beta(\gamma_j + k_x \varphi_j) + \epsilon_{Y_j}, \text{ var}(\epsilon_{Y_j}) = \sigma_{Y_j}^2$$

112 The genetic variant, G_j , for valid IVs must satisfy the following three core assumptions; (i) IV1: $\gamma_j \neq$
113 0, (ii) IV2: $\varphi_j = 0$, (iii) IV3: $\alpha_j = 0$. Furthermore, MR requires a “NO Measurement Error”
114 (NOME) assumption and an Instrument Strength Independent of Direct Effect (InSIDE) assumption.
115 It is important to assess the instrument strength to prevent weak instrument bias on MR analysis. We
116 evaluated weak instruments with mean F-statistics, and the degree of violation of the NOME

117 assumption was quantified using the previously reported I^2 statistic (ranging 0–1) (Bowden et al.,
118 2016b). Higher values for I^2 indicate lesser dilution of the causal effect estimate.

119 2.4 MR methods

120 Using all genetic variants, G_j , that satisfy the three IV assumptions and the NOME and InSIDE
121 assumptions, the causal effect of exposure on the outcome can be consistently estimated from the
122 ratio estimates and averaged using an IVW method (Burgess et al., 2013). The IVW estimate is the
123 most efficient method when all genetic variants satisfy all three IV assumptions. Cochran's Q
124 statistic was used to quantify heterogeneity (Greco et al., 2015; Bowden et al., 2017).

125 However, the estimate could be biased if one or more variants are invalid. The weighted median
126 method provides valid causal estimates, even if up to 50% of the instruments are invalid. The median
127 is unaffected by outliers, making the weighted median estimate insensitive to a pleiotropic genetic
128 variant. Causal effects are obtained from the weighted median of the ratio estimates in genetic
129 instruments, resulting in smaller standard errors receiving more weight (Bowden et al., 2016a).

130 The MR-Egger method allows all SNPs to be used as invalid instruments but requires variants to
131 satisfy the InSIDE assumption, enabling estimation of appropriate causal effects in the presence of
132 pleiotropic effects (Bowden et al., 2015). This model is suitable for linear regression and the intercept
133 term, β_{0E} , is interpreted as the average horizontal pleiotropic effect across the genetic variants
134 (Bowden et al., 2015). Rücker's Q' statistic from MR-Egger was used to quantify directional
135 heterogeneity (Greco et al., 2015; Bowden et al., 2017). If estimates of β_{0E} equal zero, the MR-Egger
136 slope estimate will be the same as the IVW estimate (Burgess and Thompson, 2015). However, when
137 the I^2 statistic quantifying the strength of NOME violation for IVs for the MR-Egger method is low,
138 a magnitude of regression dilution still occurs. In cases where the NOME assumption is violated, the
139 SIMEX method can be used to correct attenuation bias (Bowden et al., 2016b).

140 Violation of IV3 (no horizontal pleiotropy) can raise a severe bias in MR analysis. The MR-PRESSO
141 test has an advantage over MR-Egger, in that it identifies and removes pleiotropic SNPs. The test
142 comprises three parts: 1) the MR-PRESSO global test detects horizontal pleiotropy, 2) the outlier-
143 corrected causal estimate corrects for the detected horizontal pleiotropy, and 3) the MR-PRESSO
144 distortion test estimates whether the causal estimates differ significantly ($P < 0.05$) following
145 adjustment for the outliers (Verbanck et al., 2018). Therefore, MR-PRESSO results are preferable in
146 the presence of a horizontal pleiotropic effect.

147 The appropriate methods differ according to the assumptions satisfied, and the most suitable choices
148 are presented in Table 2 and 3. The IVW method is the most efficient way to estimate the causal
149 effect when all genetic variants are valid instruments (Burgess et al., 2020). In cases where the MR
150 assumption of no pleiotropy is not met, the MR-PRESSO test detects possible outliers and provides
151 consistent estimates following outlier removal (Burgess and Thompson, 2017). When some genetic
152 variants are invalid (<50%), the weighted median approach can be used as an alternative method of
153 providing a consistent estimate (Bowden et al., 2016a). By contrast, MR-Egger can obtain a causal
154 estimate by correcting directional pleiotropy but has the disadvantage of low power (Bowden et al.,
155 2015). If the NOME assumption is violated ($I^2 < 90\%$), the MR-Egger (SIMEX) method would be
156 suitable (Bowden et al., 2016b).

157

158

159 2.5 Bidirectional MR analysis

160 We conducted bidirectional MR analysis to investigate the presence of reverse causality among
161 associations between T2D-related traits and outcomes of interest. This was performed by switching
162 the exposure and outcomes in opposite directions.

163 2.6 MR power analysis

164 Power calculations were conducted at <https://sb452.shinyapps.io/power/> (Burgess et al., 2020). The
165 proportion of variance in the exposure explained by the genetic variants (R^2) were required for MR
166 power analysis, with 0.048 (FPG), 0.017 (2h-PG), and 0.024 (HbA1c) used, respectively. We
167 assumed odds ratios (ORs) of 1.1 and 1.2 for binary outcomes and changes in outcomes in standard
168 deviation (SD) units per SD change in exposure (0.1 and 0.2) for continuous outcomes. Statistical
169 power evaluations at the conservative significance level [0.007 (Bonferroni correction with 7 tests)]
170 are plotted in Figure 2.

171 3 Results

172 A total of 34, 7, and 11 genetic variants associated with FPG, 2h-PG, and HbA1c respectively, were
173 available as potential instruments from studies included in MAGIC. Each IV set showed genome-
174 wide significant ($P < 5 \times 10^{-8}$) associations with T2D-related traits and were not in LD or within
175 10,000 kb of an established signal. To investigate IV quality, we generated F-statistics, I^2 values, and
176 P -values for Cochran's Q statistic from IVW, Rucker's Q' statistic from MR-Egger, and MR-
177 PRESSO global test (Table 4). All instruments used for MR analyses had F-statistics >10 , indicating
178 no evidence of weak instrument bias. Rejection of the null hypothesis of the Cochran's Q statistic for
179 heterogeneity suggested potential pleiotropy in the genetic variants and did not indicate that the
180 InSIDE assumptions were invalid. When the pleiotropic effect was present, MR-Egger (with and
181 without SIMEX), and MR-PRESSO) were performed rather than using the IVW method. The
182 instruments corresponding to FPG satisfied the NOME assumption ($I^2 > 90$) but only partially
183 satisfied this for HbA1c ($I^2 > 90$ in only some cases) and did not satisfy this in the case of 2h-PG
184 ($I^2 < 90$). When the NOME assumption was violated, the results of MR-Egger (SIMEX) were
185 generated. Using these IVs, we performed MR analyses for a total of 14 human health phenotypes,
186 with all results (3 exposures \times 13 phenotypes \times 5 methods = 185 results) presented in Supplementary
187 Table 1. Application of Bonferroni correction to each disease category (0.05/6 = 0.008 for cancer;
188 and 0.05/7 = 0.007 for vascular disease) revealed two significant phenotypes (CAD and LDL level)
189 associated with T2D-related traits (Table 5). Additionally, we confirmed these relationships through
190 bidirectional and replication analyses (Tables 5 and 6).

191 3.1 T2D-related traits and cancers

192 We considered FPG, 2h-PG, and HbA1c as exposure traits. For FPG, IVs for lung, ovarian,
193 pancreatic, and thyroid cancer satisfied the IV assumptions (F statistics >10 , $I^2 > 90$, Q - $P > 0.05$), and
194 IVW was selected for MR analyses (Table 3). No significant causal association was observed
195 between FPG and lung ($P=0.721$), ovarian ($P=0.632$), pancreatic ($P=0.768$), and thyroid ($P=0.612$)
196 cancer. A pleiotropic effect was observed in breast cancer through Q ($P < 0.001$), Q' ($P < 0.001$)
197 statistics, and the MR-PRESSO global test ($P < 0.001$), and MR-PRESSO did not yield significant
198 outcomes ($P=0.364$). The NOME assumption was violated in SC lung cancer ($I^2 < 90$), and the MR-
199 Egger (SIMEX) method was used. The MR-Egger (SIMEX) method yielded nominally significant
200 ($P < 0.05$) causal effects ($P=0.032$). Furthermore, when 2h-PG was considered an exposure trait, IVs

201 for all cancers, except for breast cancer, we found no weak instrument bias ($F > 10$) and no
202 heterogeneity ($Q\text{-}P > 0.05$, $Q'\text{-}P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW method was
203 used. However, IVs for breast cancer have a measurement error ($I^2 < 90$), and the MR-Egger
204 (SIMEX) method was used. None of the IVs were significant for breast ($P = 0.303$), lung ($P = 0.721$),
205 SC lung ($P = 0.037$), ovarian ($P = 0.632$), pancreatic ($P = 0.768$), and thyroid ($P = 0.612$) cancer.
206 Moreover, regarding HbA1c, evidence of violations of IV assumptions for all cancers was obtained
207 (F statistics > 10 , $Q\text{-}P > 0.05$, $Q'\text{-}P > 0.05$, MR-PRESSO global test- $P > 0.05$), and IVW was applied. No
208 significant association was observed between HbA1c and breast ($P = 0.922$), lung ($P = 0.173$), SC lung
209 ($P = 0.115$), ovarian ($P = 0.719$), pancreatic ($P = 0.374$), and thyroid ($P = 0.417$) cancer.

210 For lung, breast, and ovarian cancer, we assumed an OR of 1.2 and we determined the statistical
211 power at between 40% and 70%. The highest power was observed for FPG with the highest R^2 ,
212 followed by HbA1c and 2h-PG. The estimated statistical power was the highest ($> 80\%$) for SC lung
213 cancer for all T2D-related traits owing to a sample size of $> 100,000$ individuals if the standardized
214 effect size is assumed to be same. However, for pancreatic and thyroid cancers, the sample size was
215 small (3,835 and 1,080, respectively), thus decreasing the statistical power, indicating the possibility
216 of false-negative results. The overall estimated power (Figure 2) revealed no causal effect of FPG,
217 2h-PG, and HbA1c on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers ($P < 0.008$ after
218 Bonferroni correction) (Supplementary Table 1).

219 3.2 T2D-related traits and vascular diseases

220 All data for vascular diseases were from a sample size of $> 100,000$ patients, giving them a power of
221 $\geq 80\%$, except for detecting an OR of 1.1. We found no causal effect of FPG, 2h-PG, or HbA1c on
222 CKD, HDL level, stroke, or stroke subtype, but two significant causal relationships were observed
223 for FPG with CAD and HbA1c with HDL level. Interestingly, three T2D-related traits used as criteria
224 for diagnosing T2D showed different results for the same phenotype. First, on using FPG as an
225 exposure trait, IVs for CKD and cardio-embolic stroke strongly satisfied the IV assumptions (F
226 statistics > 10 , $I^2 > 90$, F statistics > 10 , $Q\text{-}P > 0.05$, $Q'\text{-}P > 0.05$, MR-PRESSO global test- $P > 0.05$), and
227 the IVW approach was selected (Table 2). However, FPG had no causal effects on CKD ($P = 0.351$)
228 and cardio-embolic stroke ($P = 0.118$) were observed, but was nominally significant on small-vessel
229 stroke ($P = 0.025$). In the case of CAD, HDL/LDL cholesterol, and stroke, we found heterogeneity ($Q\text{-}P < 0.05$,
230 $Q'\text{-}P < 0.05$, MR-PRESSO global test- $P < 0.05$), and the MR-PRESSO method was applied.
231 Nominally significant results were observed for CAD (MR-PRESSO $P = 0.045$) and non-significant
232 results were observed for HDL cholesterol ($P = 0.265$), LDL cholesterol ($P = 0.225$), and stroke
233 ($P = 0.135$). Second, when 2h-PG was used as an exposure trait, IVs for CKD, stroke, cardio-embolic
234 stroke, and small-vessel stroke strongly satisfied the IV assumptions (F statistics > 10 , F statistics
235 > 10 , $Q\text{-}P > 0.05$, $Q'\text{-}P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW method used. Non-
236 significant causal effects were observed for 2h-PG on CKD ($P = 0.183$), stroke ($P = 0.338$), cardio-
237 embolic stroke ($P = 0.530$), and small-vessel stroke ($P = 0.084$). In the case of CAD, HDL/LDL
238 cholesterol, all have measurement error ($I^2 < 90$) with heterogeneity ($Q\text{-}P < 0.05$, $Q'\text{-}P < 0.05$, MR-
239 PRESSO global test- $P < 0.05$), and the MR-Egger (SIMEX) method was used. Non-significant causal
240 effects were observed for 2h-PG on CAD ($P = 0.301$), HDL cholesterol ($P = 0.074$), and LDL
241 cholesterol ($P = 0.241$). Third, when HbA1c was considered an exposure trait, IVs for CKD, HDL
242 cholesterol, stroke, cardio-embolic stroke and small-vessel stroke strongly satisfied the IV
243 assumptions (F statistics > 10 , $Q\text{-}P > 0.05$, $Q'\text{-}P > 0.05$, MR-PRESSO global test- $P > 0.05$), and the IVW
244 method was selected. However, no causal effects of HbA1c were observed on CKD ($P = 0.337$), HDL
245 cholesterol ($P = 0.206$), and stroke ($P = 0.567$), but there were nominally significant implications for
246 cardio-embolic stroke ($P = 0.023$) and small-vessel stroke ($P = 0.046$). Owing to the heterogeneity in

247 CAD and LDL cholesterol (Q - P <0.05, Q' - P <0.05, MR-PRESSO global test- P <0.05), the MR-
248 PRESSO method was considered, and nominally significant results were obtained for LDL
249 cholesterol (P =0.010), but non-significant for CAD (P =0.069).

250 Significant effects were found for FPG-CAD and HbA1c-LDL cholesterol. Regarding FPG-CAD, all
251 SNP-exposure and SNP-outcome effects are presented in Supplementary Table 2. We found two
252 SNPs significantly correlated with CAD (rs1260326: $P = 2.40 \times 10^{-5}$; and rs7651090: $P = 1.20 \times$
253 10^{-5}); however, given that they exhibited balanced pleiotropy, they were not excluded from the
254 analysis (but were excluded from MR-PRESSO tests). A generated funnel plot showed symmetry,
255 indicating heterogeneity due to horizontal pleiotropy (Figure 3A). The associations of the variants
256 with FPG and CAD are shown in a scatter plot with five MR-fitted lines (Figure 3B). Thirty-four
257 SNPs were considered instruments, and no weak instrument bias was noted with no violation of
258 NOME assumption, albeit with heterogeneity. Therefore, we assessed the other several sensitivity
259 methods, and observed causal effects of CAD on FPG from the weighted median (P <0.001).
260 Moreover, we verified that reverse causality did not exist (Table 6). In the replication study using the
261 same IVs and different GWAS data for outcome (PmID = 29212778, N = 296,525, P = European,
262 and unit = logOR), there was no weak instrument bias of IVs (N=34, F statistics 43.5) but the
263 heterogeneity assumption was violated (Q - P <0.05, Q' - P <0.05, MR-PRESSO global test- P <0.05).
264 Therefore, MR-PRESSO was selected, and we found that FPG has a positively causal effect on CAD
265 in accordance with the MR-PRESSO method ($P = 0.002$) (Table 5). On bidirectional MR analysis in
266 the replication study, 83 SNPs were considered instrument variables. Weak instrument bias (F-
267 statistics 77.2) and the NOME assumption ($I^2 = 92.4$) were preserved; however, heterogeneity was
268 observed Q - P <0.05, Q' - P <0.05, MR-PRESSO global test- P <0.05). MR-PRESSO revealed no causal
269 effect of CAD on FPG (Table 6).

270 Regarding HbA1c and LDL cholesterol, SNP-exposure and SNP-outcome effects (Supplementary
271 Table 3) indicated that one SNP was significantly correlated with LDL level (rs1800562; $P = 4.42 \times$
272 10^{-4}), with this SNP excluded from MR-PRESSO analysis. Figure 4A shows a funnel plot indicating
273 slight non-symmetry, suggesting the presence of heterogeneity due to horizontal pleiotropy. The
274 scatter plot in Figure 4B shows the associations of the variants with HbA1c and LDL level. Eleven
275 SNPs were considered instruments, and no weak instrument bias was noted with no violation of
276 NOME assumption, albeit with heterogeneity. Therefore, we assessed several other sensitivity
277 methods, and observed causal effects of HbA1c on LDL cholesterol from MR-Egger (SIMEX)
278 ($P = 0.007$). In addition, reverse causality was not identified (Table 6). Seventy-four SNPs were
279 considered instruments, and no weak instrument bias was noted (F-statistics 153.9), with no violation
280 of the NOME assumption ($I^2 = 97.7$). However, heterogeneity was observed (Q - P <0.05, Q' - P <0.05,
281 MR-PRESSO global test- P <0.05), and MR-PRESSO revealed no causal effect of LDL cholesterol on
282 HbA1c ($P = 0.234$). Replication analysis using the same IVs and different GWAS data for the
283 outcome-SNP effect (pmID = 28887542, N = 9,961, P = European, unit = mg/dL) revealed no
284 evidence of a weak instrument bias (N=11, F-statistics 77.6) and no heterogeneity (Q - P >0.05, Q' -
285 P >0.05, MR-PRESSO global test>0.05), but the NOME assumption ($I^2 = 87.9$) was violated.
286 Therefore, MR-PRESSO revealed significant results for the causal effect of HbA1c on LDL
287 cholesterol ($P = 0.032$) (Table 5). On bidirectional MR analysis for the replication study, 4 SNPs were
288 considered instrument variables. No weak instrument bias (F-statistics 42.9) and no heterogeneity (Q -
289 P >0.05, Q' - P >0.05, MR-PRESSO global test>0.05) were observed; however, a violation of the
290 NOME assumption ($I^2 = 4$) was noted. Accordingly, IVW was considered, and no causal effect of
291 LDL cholesterol on HbA1c was observed ($P = 0.681$) (Table 6).

292 **4 Discussion**

293 In this study, we performed MR analysis of the effect of T2D-related traits on 13 human health
294 phenotypes using GWAS results and data from the MR-BASE registry. In particular, MR analysis
295 was conducted according to three T2D-related criteria (FPG and 2h-PG from the OGTT and HbA1c).
296 MR analyses reduce potential confounding effects and reverse causation, and our results are
297 concurrent with those of previous epidemiological studies. Previous large meta-analyses or
298 systematic reviews of epidemiological studies show that the association between T2D and cancer
299 development is unclear (Tsilidis et al., 2015). Moreover, most epidemiological studies report
300 limitations in findings of T2D-related association with cancers, because they were based on self-
301 reported health assessments with high specificity (>90%) but low sensitivity (66%) as compared with
302 medical records (Okura et al., 2004). Recently, results of MR analysis indicated no strong evidence
303 supporting a causal relationship between T2D and major solid tumors (stomach, colorectal, liver,
304 pancreas, lung, breast, and prostate) (Goto et al., 2020). Similarly, in the present study, analysis of
305 European data from the MR-Base registry revealed no significant causal effect of T2D-related traits
306 on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers. Although T2D and cancer share a
307 number of risk factors, such as hyperglycemia, insulin resistance, and dyslipidemia, a relationship
308 between the diseases has not been fully demonstrated (Vigneri et al., 2009). Additionally, studies
309 have reported correlations between hypoglycemic agents and cancer incidence, although these
310 findings remain controversial (Alimova et al., 2009;Currie et al., 2009).

311 In T2D patients, the risk of death from cardiovascular disease increases along with elevated FPG and
312 HbA1c levels, with HbA1c level correlated with microvascular and microvascular complications
313 (Kannel and McGee, 1979;Group, 1998;Okura et al., 2004). Therefore, hyperglycemia represents a
314 strong independent factor for cardiovascular disease, with the risk increasing 2- to 3-fold in men and
315 3- to 4-fold women diagnosed with T2D relative to those without T2D (Kannel and McGee,
316 1979;Okura et al., 2004). A longitudinal study involving follow-up for 8 years of 2,363 non-diabetic
317 adults between the ages of 50 and 75 years reported significant association between 2h-PG and
318 HbA1c levels and an increased risk of death from cardiovascular disease (De Vegt et al., 1999).
319 Moreover, that study identified HbA1c level as not only predictive of improved better mortality from
320 cardiovascular disease relative to FPG and 2h-PG (Park et al., 1996) but also an independent risk
321 factor for atherosclerosis and cardiovascular disease independent of T2D (Nakamura et al.,
322 1993;Kanauchi et al., 2001). In the present study, our findings indicated that vascular disease and
323 LDL level were significantly linked with HbA1c level but not FPG or 2h-PG.

324 We found that different characteristics related to FPG, 2h-PG, and HbA1c differentially influenced
325 IV characteristics. The 2h-PG results from an OGTT represent a standard test for T2D diagnosis.
326 Although 2h-PG testing is more highly sensitive and specific than FPG testing, its low
327 reproducibility is a disadvantage (Peters et al., 1996). The low reproducibility is a consequence of
328 changes in 2-h glucose concentrations for each measurement within a 48-h or 1-week time period in
329 the same individual. On the other hand, FPG testing is simple and reproducible; however, the
330 sensitivity for T2D diagnosis is poor, because it does not allow accurate identification of
331 hyperglycemia after glucose load (Davidson et al., 1999). HbA1c reflects overall tissue protein
332 glycation and can better reflect the overall biological effect of blood sugar as a 3-month average
333 blood sugar estimate (Peterson et al., 1998); however, HbA1c measurements can be affected by
334 hemoglobin disease, chronic renal failure, testing methods, and/or specific dosage (Barr et al., 2002).
335 Therefore, these findings suggest that the measurement error associated with SNP-exposure
336 associations might be large when using any of these criteria. A previous study showed that
337 calculation of the I^2 value confirmed the inadequacy of the NOME assumption due to measurement

338 error related to 2h-PG testing (Bowden et al., 2016b). Furthermore, reports indicated that the HbA1c
339 level shows less variability in day-to-day within-person variance than FPG (<2% for HbA1c vs. 12–
340 15% for FPG) (Ollerton et al., 1999), and the intra-individual coefficient of variation for FPG (6.4%)
341 is less than that for 2h-PG (16.7%) (Mooy et al., 1996). Therefore, MR analysis using 2h-PG as an
342 exposure can be expected to increase the reliability of MR-Egger (SIMEX) findings relative to other
343 methods. In the cases of FPG and HbA1c, IVW results and the sensitivity analysis methods should be
344 examined more broadly.

345 We performed MR analysis using public data from previous large-scale GWAS studies. Producing
346 in-house genetic data is expensive and requires substantial human resources, making it difficult for
347 many individual researchers lacking access to appropriate datasets. A two-sample MR approach
348 represents an effective method for discovering novel causal relationships through the use of available
349 large-scale GWAS datasets. Additionally, MR analysis excludes confounding effects by using SNPs
350 associated with exposure as genetic instruments, which also reduces the adverse effects of inaccurate
351 data on hindering identification of relationships between exposure and outcome.

352 The present MR analysis has several limitations. First, some subjects may have overlapped between
353 the two data sets with respect to the estimates of instrument-exposure and instrument-outcome, which
354 could lead to inflated type 1 error rates and false-positive findings (Burgess et al., 2016).
355 Furthermore, MR analyses are based on the GWAS. GWAS requires numerous subjects, often in
356 multiple cohorts. Disease definition can differ among different cohorts. Third, we mostly included
357 studies involving a predominantly European population with few individuals of other ancestries
358 (mixed); hence, the present results may not be applicable to other racial backgrounds. Nevertheless,
359 the present results support the results of previous epidemiology studies and promote further studies in
360 this field.

361 **5 Conflict of Interest**

362 The authors declare that the research was conducted in the absence of any commercial or financial
363 relationships that could be construed as a potential conflict of interest.

364 **6 Author Contributions**

365 J.J. analyzed and interpreted the results and wrote the manuscript. S.W. and S.L. designed the study.
366 All authors revised this paper critically for important intellectual content.

367 **7 Funding**

368 This study was supported by the National Research Foundation of Korea (2017M3A9F3046543).

369 **8 Acknowledgements**

370 None

371 **9 Data Availability Statement**

372 All datasets presented in this study are included in the supplementary material and available at
373 <https://www.mrbase.org/> and <https://gwas.mrcieu.ac.uk/>.

375 **10 References**

- 376 Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., and Thor, A.D. (2009).
377 Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest
378 in vitro. *Cell Cycle* 8, 909-915.
- 379 Association, A.D. (2010). Standards of medical care in diabetes—2010. *Diabetes Care* 33, S11-S61.
- 380 Barr, R.G., Nathan, D.M., Meigs, J.B., and Singer, D.E. (2002). Tests of glycemia for the diagnosis
381 of type 2 diabetes mellitus. *Ann. Int. Med.* 137, 263-272.
- 382 Bax, J.J., Young, L.H., Frye, R.L., Bonow, R.O., Steinberg, H.O., and Barrett, E.J. (2007). Screening
383 for coronary artery disease in patients with diabetes. *Diabetes Care* 30, 2729-2736.
- 384 Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid
385 instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.*
386 44, 512-525.
- 387 Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016a). Consistent estimation in
388 Mendelian randomization with some invalid instruments using a weighted median estimator.
389 *Genet. Epidemiol.* 40, 304-314.
- 390 Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N.A., and Thompson, J.R.
391 (2016b). Assessing the suitability of summary data for two-sample Mendelian randomization
392 analyses using MR-Egger regression: the role of the I² statistic. *Int. J. Epidemiol.* 45, 1961-
393 1974.
- 394 Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017). A
395 framework for the investigation of pleiotropy in two-sample summary data Mendelian
396 randomization. *Stat. Med.* 36(11), 1783-1802.
- 397 Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian randomization analysis with
398 multiple genetic variants using summarized data. *Genet. Epidemiol.* 37, 658-665.
- 399 Burgess, S., Davies, N.M., and Thompson, S.G. (2016). Bias due to participant overlap in two-
400 sample Mendelian randomization. *Genet. Epidemiol.* 40, 597-608.
- 401 Burgess, S., Smith, G.D., Davies, N.M., Dudbridge, F., Gill, D., Glymour, M.M., Hartwig, F.P.,
402 Holmes, M.V., Minelli, C., and Relton, C.L. (2020). Guidelines for performing Mendelian
403 randomization investigations. *Wellcome Open Research* 4, 186.
- 404 Burgess, S., and Thompson, S.G. (2015). *Mendelian randomization: methods for using genetic*
405 *variants in causal estimation*. CRC Press.
- 406 Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian randomization using
407 the MR-Egger method. *Eur. J. Epidemiol.* 32, 377-389.
- 408 Collaboration, E.R.F. (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N.*
409 *Engl. J. Med.* 364, 829-841.
- 410 Currie, C., Poole, C., and Gale, E. (2009). The influence of glucose-lowering therapies on cancer risk
411 in type 2 diabetes. *Diabetologia* 52, 1766-1777.
- 412 Davidson, M.B., Schriger, D.L., Peters, A.L., and Lorber, B. (1999). Relationship between fasting
413 plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2
414 diabetes using new diagnostic criteria. *JAMA* 281, 1203-1210.

- 415 De Vegt, F., Dekker, J., Ruhe, H., Stehouwer, C., Nijpels, G., Bouter, L., and Heine, R. (1999).
416 Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn
417 population: the Hoorn Study. *Diabetologia* 42, 926-931.
- 418 Gavin Iii, J.R., Alberti, K., Davidson, M.B., and DeFronzo, R.A. (1997). Report of the expert
419 committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 20, 1183.
- 420 Gleissner, C.A., Galkina, E., Nadler, J.L., and Ley, K. (2007). Mechanisms by which diabetes
421 increases cardiovascular disease. *Drug Discov. Today: Dis. Mech.* 4, 131-140.
- 422 Goto, A., Yamaji, T., Sawada, N., Momozawa, Y., Kamatani, Y., Kubo, M., Shimazu, T., Inoue, M.,
423 Noda, M., and Tsugane, S. (2020). Diabetes and cancer risk: A Mendelian randomization
424 study. *nt. J. Cancer* 146, 712-719.
- 425 Greco M, F. D., Minelli, C., Sheehan, N. A., & Thompson, J. R. (2015). Detecting pleiotropy in
426 Mendelian randomisation studies with summary data and a continuous outcome. *Stat. Med.*
427 34(21), 2926-2940.
- 428 Group, U.P.D.S. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared
429 with conventional treatment and risk of complications in patients with type 2 diabetes
430 (UKPDS 33). *The Lancet* 352, 837-853.
- 431 Hemani, G., Zheng, J., Wade, K.H., Laurin, C., Elsworth, B., Burgess, S., Bowden, J., Langdon, R.,
432 Tan, V., and Yarmolinsky, J. (2016). MR-Base: a platform for systematic causal inference
433 across the phenome using billions of genetic associations. *BioRxiv*, 078972.
- 434 Johnson, J., Carstensen, B., Witte, D., Bowker, S., Lipscombe, L., Renehan, A., Diabetes, and
435 Consortium, C.R. (2012). Diabetes and cancer (1): evaluating the temporal relationship
436 between type 2 diabetes and cancer incidence. *Diabetologia* 55, 1607-1618.
- 437 Kanauchi, M., Tsujimoto, N., and Hashimoto, T. (2001). Advanced glycation end products in
438 nondiabetic patients with coronary artery disease. *Diabetes Care* 24, 1620-1623.
- 439 Kannel, W.B., and Mcgee, D.L. (1979). Diabetes and cardiovascular disease: the Framingham study.
440 *JAMA* 241, 2035-2038.
- 441 Laakso, M. (1999). Hyperglycemia and cardiovascular disease in type 2 diabetes. *Diabetes* 48, 937-
442 942.
- 443 Mooy, J., Grootenhuys, P., De Vries, H., Kostense, P., Popp-Snijders, C., Bouter, L., and Heine, R.
444 (1996). Intra-individual variation of glucose, specific insulin and proinsulin concentrations
445 measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn
446 Study. *Diabetologia* 39, 298-305.
- 447 Nakamura, Y., Horii, Y., Nishino, T., Shiiki, H., Sakaguchi, Y., Kagoshima, T., Dohi, K., Makita, Z.,
448 Vlassara, H., and Bucala, R. (1993). Immunohistochemical localization of advanced
449 glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. *Am.*
450 *J. Pathol.* 143, 1649.
- 451 Nathan, D., Turgeon, H., and Regan, S. (2007). Relationship between glycated haemoglobin levels
452 and mean glucose levels over time. *Diabetologia* 50, 2239-2244.
- 453 Nathan, D.M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., and Heine, R.J. (2008). Translating
454 the A1C assay into estimated average glucose values. *Diabetes Care* 31, 1473-1478.
- 455 Nesto, R. (2001). CHD: a major burden in type 2 diabetes. *Acta Diabetol.* 38, S3-S8.

- 456 Okura, Y., Urban, L.H., Mahoney, D.W., Jacobsen, S.J., and Rodeheffer, R.J. (2004). Agreement
457 between self-report questionnaires and medical record data was substantial for diabetes,
458 hypertension, myocardial infarction and stroke but not for heart failure. *J. Clin. Epidemiol.*
459 *57*, 1096-1103.
- 460 Ollerton, R.L., Playle, R., Ahmed, K., Dunstan, F.D., Luzio, S.D., and Owens, D.R. (1999). Day-to-
461 day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects.
462 *Diabetes Care* *22*, 394-398.
- 463 Park, S., Barrett-Connor, E., Wingard, D.L., Shan, J., and Edelstein, S. (1996). GHb is a better
464 predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women
465 without diabetes: the Rancho Bernardo Study. *Diabetes Care* *19*, 450-456.
- 466 Peters, A.L., Davidson, M.B., Schriger, D.L., and Hasselblad, V. (1996). A clinical approach for the
467 diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. *JAMA* *276*,
468 1246-1252.
- 469 Peterson, K.P., Pavlovich, J.G., Goldstein, D., Little, R., England, J., and Peterson, C.M. (1998).
470 What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization
471 mass spectrometry. *Clin. Chem.* *44*, 1951-1958.
- 472 Scott, R.A., Lagou, V., Welch, R.P., Wheeler, E., Montasser, M.E., Mägi, R., Strawbridge, R.J.,
473 Rehnberg, E., Gustafsson, S., and Kanoni, S. (2012). Large-scale association analyses identify
474 new loci influencing glycemic traits and provide insight into the underlying biological
475 pathways. *Nat. Genet.* *44*, 991.
- 476 Tsilidis, K.K., Kasimis, J.C., Lopez, D.S., Ntzani, E.E., and Ioannidis, J.P. (2015). Type 2 diabetes
477 and cancer: umbrella review of meta-analyses of observational studies. *BMJ.* *350*, g7607.
- 478 Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread horizontal
479 pleiotropy in causal relationships inferred from Mendelian randomization between complex
480 traits and diseases. *Nat. Genet.* *50*, 693-698.
- 481 Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009). Diabetes and cancer.
482 *Endocr.-Relat. Cancer* *16*, 1103-1123.
- 483 Young, L.H., Frans, J.T., Chyun, D.A., Davey, J.A., Barrett, E.J., Taillefer, R., Heller, G.V.,
484 Iskandrian, A.E., Wittlin, S.D., and Filipchuk, N. (2009). Cardiac outcomes after screening
485 for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a
486 randomized controlled trial. *JAMA* *301*, 1547-1555.

487

488

489

490

491

492

493

494 **Table 1.** Description of data from MR-Base based on the phenotype

Category	Trait	Consortium/ First author	PubMed ID	Unit	No. of cases	No. of controls	No. of SNPs	Population
1. Cancer								
	Breast cancer	BCAC	25751625	LogOR	15,748	18,084	13,011,123	European
	Lung cancer	ILCCO	24880342	LogOR	11,348	15,861	8,945,893	European
	Lung cancer (SC)	ILCCO	24880342	LogOR	3,275	150,038	8,893,750	European
	Ovarian cancer	OCAC	28346442	LogOR	1,366	40,941	11,403,952	European
	Pancreatic cancer	PanScan1	19648918	LogOR	1,896	1,939	521,863	European
	Thyroid cancer	Kohler A	23894154	LogOR	649	431	572,028	European
2. Vascular disease								
	CAD	VanderHarst P	29212778	LogOR	122,733	424,528	7,934,254	European
	CKD	CKDGen	26831199	LogOR	12,385	104,780	2,191,877	Mixed
	HDL cholesterol	GLGC	24097068	SD	—	187,167	2,447,442	Mixed
	LDL cholesterol	GLGC	24097068	SD	—	173,082	2,437,752	Mixed
	Stroke	Malik R	29531354	LogOR	40,585	406,111	7,633,440	European
	(Cardio-embolic)	Malik R	29531354	LogOR	7,193	406,111	8,271,294	European
	(Small-vessel)	Malik R	29531354	LogOR	5,386	192,662	6,150,261	European

495 SC, squamous cell; SD, standard deviation; CKD, chronic kidney disease; CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high-density
496 lipoprotein; logOR, log odds ratio.

497 **Table 2.** Recommended MR methods by assumption of IVs

No weak IVs (F>10)	NOME	No Heterogeneity	Recommended Methods
Satisfied	Satisfied	Satisfied	IVW
Satisfied	Satisfied	At least one violated	→Table 3
Satisfied	Violated	Satisfied	IVW
Satisfied	Violated	At least one violated	MR-Egger (SIMEX)
Violated	Satisfied	Satisfied	Weighted median
Violated	Satisfied	At least one violated	→Table 3
Violated	Violated	Satisfied	MR-Egger (SIMEX)
Violated	Violated	At least one violated	MR-Egger (SIMEX)

498 IV, instrument variable; NOME, NO Measurement Error; IVW, inverse-variance-weighted; SIMEX,
 499 simulation extrapolation;

500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519

520 **Table 3.** Recommended MR methods by heterogeneity test

Q test [†]	Q' test [†]	MR-PRESSO global test [‡]	Recommended Methods
			IVW
✓	✓		MR-Egger
	✓		IVW
✓			MR-Egger
		✓	IVW, if there is no weak IV MR-PRESSO, otherwise
✓	✓	✓	MR-PRESSO
	✓	✓	IVW, if there is no weak IV (F>10) MR-PRESSO, ow (F<10)
✓		✓	MR-Egger, MR-PRESSO

521 ✓: significant (heterogeneity exists)

522 [†]Greco et al., 2015; Bowden et al., 2017

523 [‡] Verbanck et al., 2018

524 IV, instrument variable; IVW, inverse-variance-weighted; MR-PRESSO, MR-Pleiotropy RESidual Sum and
525 Outlier

526

527

528

529 **Table 4.** Assumption check for instrumental variables

	FPG ($R^2 = 0.048$)				2h-PG ($R^2 = 0.017$)				HbA1c ($R^2 = 0.024$)			
	N	F	I^2 (%)	Q Q' RSS	N	F	I^2 (%)	Q Q' RSS	N	F	I^2 (%)	Q Q' RSS
1. Cancer												
Breast cancer	34	130.5	96.8	<0.001 <0.001 <0.001	7	43.5	29.8	<0.001 0.019 0.023	11	77.6	92.2	0.110 0.249 0.371
Lung cancer	33	133.0	97.3	0.182 0.183 0.211	7	43.5	36.2	0.322 0.397 0.258	11	77.6	87.6	0.021 0.063 0.089
SC lung cancer	33	43.5	40.1	0.599 0.553 0.477	7	43.5	40.1	0.875 0.786 0.913	11	77.6	87.9	0.198 0.154 0.216
Ovarian cancer	33	133.5	97.4	0.530 0.490 0.412	7	43.5	28.1	0.323 0.224 0.362	11	77.6	87.8	0.243 0.334 0.298
Pancreatic cancer	25	111.7	96.4	0.138 0.122 0.199	6	45.0	31.8	0.710 0.594 0.642	8	82.1	90.9	0.239 0.186 0.214
Thyroid cancer	27	144.9	97.9	0.183 0.248 0.275	5	47.4	21.9	0.434 0.703 0.621	9	81.7	91.2	0.882 0.899 0.885
2. Cardiovascular disease												
CAD	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	23.0	<0.001 <0.001 <0.001	11	77.6	88.0	0.002 0.014 0.018
CKD	32	135.8	97.4	0.106 0.114 0.151	7	43.5	29.1	0.482 0.451 0.395	10	82.1	86.5	0.632 0.548 0.421
HDL cholesterol	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	2.4	<0.001 <0.001 <0.001	11	77.6	90.9	0.545 0.589 0.436
LDL cholesterol	34	130.8	97.2	<0.001 <0.001 <0.001	7	43.5	5.7	<0.001 <0.001 <0.001	11	77.6	91.1	<0.001 <0.001 <0.001
Stroke	34	130.5	97.3	<0.001 <0.001 <0.001	7	43.5	39.9	0.069 0.051 0.067	11	77.6	86.0	0.075 0.084 0.092
(Cardio-embolic)	34	130.5	97.4	0.498 0.649 0.557	7	43.4	35.2	0.733 0.611 0.694	11	77.6	88.7	0.255 0.247 0.275
(Small-vessel)	32	135.8	97.6	0.038 0.130 0.199	7	43.5	55.6	0.675 0.636 0.645	10	76.88	86.6	0.556 0.522 0.512

530 F, F-statistic; Q, P -value for the Q-test from IVW; Q', P -value for the Q'-test from MR-Egger; RSS, P -value
 531 for MR-PRESSO global test, SC, squamous cell; CKD, chronic kidney disease; CAD, coronary artery disease;
 532 LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose; 2h-PG, 2-h plasma
 533 glucose; HbA1, hemoglobin A1c.

534 **Table 5.** Significant results from MR and replication analyses

No.	Exposure	Outcome	Original study				Replication study			
			MR method	Parameter	N	Estimate (95% CI)	P	N	Estimate (95% CI)	P
1	FPG	CAD	IVW	Estimate	34	0.21 (0.05, 0.37)	0.012	34	0.14 (-0.02, 0.29)	0.078
			MR Egger	Intercept		0.00 (-0.01, 0.01)	0.530		0.01 (0.00, 0.02)	0.090
				Slope		0.13 (-0.18, 0.43)	0.426		-0.07 (-0.36, 0.22)	0.626
			MR Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.443		0.00 (-0.01, 0.01)	0.769
				Slope		0.22 (0.06, 0.39)	0.014		0.144 (-0.02, 0.30)	0.087
			MR-PRESSO (O-C)	Estimate	32	0.18 (0.01, 0.35)	0.045	28	0.19 (0.07, 0.32)	0.002
Weighted median	Estimate			0.29 (0.14, 0.45)	<0.001		0.20 (0.07, 0.34)	0.003		
2	HbA1c	LDL cholesterol	IVW	Estimate	11	0.23 (0.05, 0.41)	0.015	10	0.15 (-0.31, 0.61)	0.521
			MR Egger	Intercept		-0.01 (-0.03, 0.01)	0.281		-0.05 (-0.08, -0.01)	0.004
				Slope		0.45 (0.01, 0.88)	0.046		0.14 (0.39, 1.89)	0.003
			MR Egger (SIMEX)	Intercept		-0.01 (-0.02, 0.00)	0.053		0.00 (-0.02, 0.02)	0.780
				Slope		0.27 (0.11, 0.44)	0.007		0.16 (-0.33, 0.65)	0.539
			MR-PRESSO (O-C)	Estimate	10	0.14 (0.03, 0.25)	0.010	9	0.38 (0.03, 0.72)	0.032
Weighted median	Estimate			0.15 (0.03, 0.26)	0.012		0.44 (0.03, 0.84)	0.036		

535 MR, Mendelian randomization; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and
536 Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; Hb1Ac,
537 hemoglobin A1c.

538
539
540
541
542
543
544
545
546
547

548 **Table 6.** Significant results from bidirectional MR analysis

No.	Exposure	Outcome	Original study					Replication study			
			MR methods	parameter	N	Estimate (95% CI)	P	N	Estimate (95% CI)	P	
1	CAD	FPG	IVW	Estimate	30	0.00 (−0.02, 0.02)	0.873	83	0.00 (−0.01, 0.01)	0.834	
				MR Egger	Intercept		0.00 (−0.01, 0.01)		0.352	0.00 (−0.01, 0.01)	0.813
					Slope		−0.02 (−0.06, 0.02)		0.437	0.00 (−0.02, 0.03)	0.906
			MR Egger (SIMEX)	Intercept		0.00 (−0.01, 0.01)	0.435		0.00 (−0.01, 0.01)	0.907	
				Slope		0.01 (−0.01, 0.02)	0.781		0.00 (−0.01, 0.01)	0.844	
			MR-PRESSO (O-C)	Estimate	29	0.00 (−0.02, 0.02)	0.877		No outlier	—	
			Weighted median	Estimate		0.01 (−0.01, 0.03)	0.186		0.00 (−0.01, 0.01)	0.834	
2	LDL cholesterol	HbA1c	IVW	Estimate	74	0.02 (−0.01, 0.05)	0.202	4	−0.01 (−0.04, 0.03)	0.681	
				MR Egger	Intercept		0.00 (−0.01, 0.01)		0.263	0.00 (−0.02, 0.02)	0.796
					Slope		−0.01 (−0.06, 0.05)		0.859	−0.02 (−0.13, 0.09)	0.719
			MR Egger (SIMEX)	Intercept		0.02 (−0.01, 0.00)	0.056		0.00 (−0.01, 0.01)	0.513	
				Slope		0.02 (−0.01, 0.05)	0.158		−0.02 (−0.03, 0.01)	0.548	
			MR-PRESSO (O-C)	Estimate	71	0.02 (−0.01, 0.04)	0.234		Not enough IVs	—	
			Weighted median	Estimate		−0.01 (−0.03, 0.03)	0.911		−0.02 (−0.04, 0.02)	0.376	

549 MR, Mendelian randomization; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and
550 Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; HbA1c,
551 hemoglobin A1c.

552 11 **Figure Legends**

553 **Figure 1.** Causal directed acyclic graph for MR analysis.

554 MR, Mendalian randomization.

555 **Figure 2.** Statistical power evaluations of MR analyses based on the T2D-diagnosis criteria. (A) FPG, (B)
556 2h-PG, and (C) HbA1c. We used a conservative significance threshold of $P < 0.007$ with Bonferroni
557 correction using 7 of testing.


558 MR, Mendalian randomization; T2D, type 2 diabetes; FPG, fasting plasma glucose; 2h-PG, 2-h plasma
559 glucose; HbA1c, hemoglobin A1c; OR, odds ratio; SD, standard deviation.

560 **Figure 3.** MR analysis of the effect of FPG on CAD. (A) Funnel plot displaying individual causal
561 effect estimates for FPG on CAD. Dots representing the estimated causal effect for each IV. (B) The
562 association between the effect size estimates on the FPG (X-axis) and CAD (Y-axis) for all SNPs that
563 served as IVs.


564 FPG, fasting plasma glucose; CAD, coronary artery disease; IV, instrumental variable; SNP, single-
565 nucleotide polymorphism; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual
566 Sum and Outlier (outlier-correction).

567 **Figure 4.** MR analysis of the effect of HbA1c on LDL levels. (A) Funnel plot displaying individual
568 causal effect estimates for HbA1c on LDL levels. Dots represent the estimated causal effect for each
569 IV. (B) The relationship between the effect size estimates on HbA1c (X-axis) and LDL level (Y-axis)
570 for all SNPs that served as IVs.


571 MR, Mendalian randomization; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; IV,
572 instrumental variable; SNP, single-nucleotide polymorphism; SIMEX, simulation extrapolation;
573 PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction).



Fasting Plasma Glucose



2hr Postload Glucose



HbA1c

